Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

Sep 27, 2022

Read More

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

Sep 20, 2022

Read More

Zai Lab’s Statement Regarding U.S./China Agreement Concerning PCAOB Inspection and Review of Auditors

Aug 26, 2022

Read More

Zai Lab Announces Participation in September Investor Conferences

Aug 23, 2022

Read More

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

Aug 09, 2022

Read More

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Aug 08, 2022

Read More

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

Jul 19, 2022

Read More

Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs

Jul 17, 2022

Read More